Search results
Showing 1 to 15 of 33 results for varicose vein
This guideline covers diagnosing and managing varicose veins in people aged 18 and over. It aims to ensure that people understand the options for treating varicose veins and that healthcare professionals know when to refer people for specialist assessment and treatment.
This quality standard covers diagnosing and managing varicose veins in the legs of adults (aged 18 and over). It includes referral for specialist assessment and treatment options. It describes high-quality care in priority areas for improvement.
All NICE products on varicose veins. Includes any guidance and quality standards.
Endovenous mechanochemical ablation for varicose veins (HTG414)
Evidence-based recommendations on endovenous mechanochemical ablation for varicose veins. This involves using a rotating wire and chemical to close the varicose vein.
Transilluminated powered phlebectomy for varicose veins (HTG16)
Evidence-based recommendations on transilluminated powered phlebectomy for varicose veins. This involves using a special light passed underneath the skin to see the veins and removing them by suction.
View recommendations for HTG16Show all sections
Sections for HTG16
Ultrasound-guided foam sclerotherapy for varicose veins (HTG301)
Evidence-based recommendations on ultrasound guided foam sclerotherapy for varicose veins. This involves mixing a chemical with air or another gas to produce a foam, which is injected into the affected vein using ultrasound imaging to monitor its progress.
View recommendations for HTG301Show all sections
Sections for HTG301
Evidence-based recommendations on cyanoacrylate glue occlusion for varicose veins. This involves injecting medical glue (cyanoacrylate) into a vein to close it with the aim of improving symptoms.
View recommendations for HTG540Show all sections
Evidence-based recommendations on radiofrequency ablation of varicose veins. This involves using radiofrequency energy to heat the wall of the vein so that it collapses.
View recommendations for HTG2Show all sections
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
ischaemic attack in over 16s: diagnosis and initial management - Varicose veins: diagnosis and management - Venous...
Endovenous laser treatment of the long saphenous vein (HTG26)
Evidence-based recommendations on endovenous laser treatment of the long saphenous vein. This involves using laser and heat to seal up the vein.
View recommendations for HTG26Show all sections
Sections for HTG26
This quality standard covers reducing the risk of venous thromboembolism (VTE) in people aged 16 and over who are in hospital. It also covers diagnosing and treating VTE in all people aged 18 and over. It describes high-quality care in priority areas for improvement.
View quality statements for QS201Show all sections
Sections for QS201
- Quality statements
- Quality statement 1: Timing of pharmacological venous thromboembolism prophylaxis
- Quality statement 2: Venous thromboembolism risk assessment for people with lower limb immobilisation
- Quality statement 3: Proximal leg vein ultrasound scan for a 'likely' deep vein thrombosis Wells score
- Quality statement 4: Venous thromboembolism anticoagulation review
- Quality statement 5: Follow-up for outpatients with low-risk pulmonary embolism
- Update information
- About this quality standard
ID CG168/1 Question Natural history of varicose veins:- In people with varicose veins at CEAP...
compression hosiery versus no compression for the management of symptomatic varicose veins? Any explanatory notes(if...
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.